GlassScriptPhysician profile
Parand Alavi
NPI 1801976139
$18,119.92
in general payments reported to CMS, 2019-2025
68 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,260 · 2020: $1,604 · 2021: $2,797 · 2022: $3,078 · 2023: $2,917 · 2024: $2,788 · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,370 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,369.70 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,225.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,971.12 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,637.92 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,441.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,096.10 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $1,068.59 | 2019-2025 | |
| Pfizer INC. | $1,058.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $688.49 | 2019-2025 | |
| Amgen INC. | $671.21 | 2019-2025 | Otezla, Repatha, Repatha |
| Horizon Therapeutics Plc | $567.59 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $416.53 | 2021-2024 | |
| Exact Sciences Corporation | $374.29 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $341.73 | 2019-2024 | Fanapt, Hetlioz |
| Amarin Pharma, INC. | $331.79 | 2019-2023 | |
| Corcept Therapeutics | $313.15 | 2025 | Korlym |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parand Alavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.